A standardized questionnaire regarding the composition of patients treated for CLL/SLL, disease diagnosis and prognosis evaluation, concomitant diseases, organ function evaluation, treatment selection, and Bruton tyrosine kinase(BTK)inhibitor was used. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.